Kyverna Therapeutics (KYTX) Proxy filing summary

Executive summary

• 2025 was a transformative year, highlighted by registrational data in stiff person syndrome (SPS) and interim Phase 2 data in generalized myasthenia gravis (gMG), advancing the company’s autoimmune CAR T pipeline and financial position into 2028.

• The company is preparing for a BLA filing for miv-cel in SPS in the first half of 2026 and is executing a Phase 3 trial in gMG.

• Leadership and board were strengthened to support commercial transition and future growth.

Voting matters and shareholder proposals

• Stockholders are asked to elect two Class II directors (Ian Clark and Christi Shaw) to serve until 2029.

• Ratification of BDO USA, P.C. as independent registered public accounting firm and auditor for 2026 is proposed.

• Board recommends voting FOR both proposals.

Board of directors and corporate governance

• Board consists of eight directors divided into three staggered classes, with a majority deemed independent under Nasdaq rules.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, and Science and Technology, all composed of independent directors.

• Corporate Governance Guidelines and a Code of Business Conduct and Ethics are in place.

• Board leadership is separated between the Executive Chairperson and CEO.